Arcutis Biotherapeutics, Inc. (NasdaqGS: ARQT)
Health Care · Biotechnology · US
$26.43
-0.56% today · +28.3% 1Y
Arcutis Biotherapeutics, Inc. (NasdaqGS: ARQT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.34B and employs 354 people.
Over the last twelve months the share price has gained 28.3%, trading between 19.30 and 31.77.
Tweenvest scores Arcutis Biotherapeutics, Inc. across four factors: quality 39/100, value 36/100. Its strongest factor is quality.
ARQT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.34B
- Revenue (TTM)
- $463.98M
- P/E
- 123.39
- EPS
- 0.22
- Dividend yield
- —
- Beta (5Y)
- 1.58
- 52-week high
- $31.77
- 52-week low
- $19.30
- Avg volume (3M)
- —
- Shares outstanding
- 125.69M
- Employees
- 354
- Next earnings
- —
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
- ISIN
- US03969K1088
- Founded
- 2016
- Listed since
- Jan 31, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Walvax Biotechnology Co., Ltd.SZSE: 300142 | $3.52B | CN¥14.75 | +3.65% |
| IDEAYA Biosciences, Inc.NasdaqGS: IDYA | $3.48B | $36.15 | +0.11% |
| InnoCare Pharma LimitedSEHK: 9969 | $3.46B | HK$12.73 | -6.60% |
| Acadia Pharmaceuticals Inc.NasdaqGS: ACAD | $3.41B | $19.59 | -0.96% |
| Viking Therapeutics, Inc.NasdaqCM: VKTX | $3.33B | $28.43 | -0.28% |
| Celcuity Inc.NasdaqCM: CELC | $3.32B | $65.81 | -3.14% |
| CareDx, Inc.NasdaqGM: CDNA | $3.29B | $61.73 | -3.05% |
| Denali Therapeutics Inc.NasdaqGS: DNLI | $3.11B | $19.09 | -1.85% |
Figures last refreshed Oct 11, 2026.